Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tavolimab, an antibody targeting OX40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enapotamab, an antibody targeting AXL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Berlimatoxumab, an antibody targeting Staphylococcus aureus Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atidortoxumab, an antibody targeting Staphylococcus aureus Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Quetmolimab, an antibody targeting CX3CL1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Osocimab, an antibody targeting F11.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gancotamab, an antibody targeting HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etokimab, an antibody targeting IL13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zuberitamab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bersanlimab, an antibody targeting ICAM1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Modakafusp, an antibody targeting ADPRC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gremubamab, an antibody targeting PcrV type III secretion system × Polysaccharide synthesis locus (Pseudomonas).